VAV1

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 14, 2024
Rat, Finance, Patient, Roche, Food and Drug Administration, Therapy, GLP, Rheumatology, Inflammasome, Research, Triple-negative breast cancer, CDK2, Public expenditure, Investigational New Drug, Cancer, VAV1, MGD, Prostate cancer, NSCLC, PD, Neoplasm, Inflammation, Senior, Dermatology, AACR, MYC, Poster, FDA, SCLC, DSM-IV codes, Administration, Growth, Fast Track, NLRP3, Toxicology, Research and development, Pharmaceutical industry

“We made excellent pipeline and corporate progress during 2023 and early 2024, highlighted by the encouraging initial clinical results reported from our MRT-2359 Phase 1/2 study in October.

Key Points: 
  • “We made excellent pipeline and corporate progress during 2023 and early 2024, highlighted by the encouraging initial clinical results reported from our MRT-2359 Phase 1/2 study in October.
  • Edmund has more than 25 years of experience as a finance professional and has been with Monte Rosa since March of 2021.
  • Monte Rosa expects to subsequently initiate proof-of-concept studies in autoimmune diseases spanning gastroenterology, dermatology, rheumatology, and neurology indications.
  • The increase of $54 million was primarily related to the proceeds from the Roche collaboration and registered direct offering in Q4 2023.

Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
Research and development, American College, IND, MGD, PD, Public expenditure, Investigational New Drug, G&A, Inflammation, Treatment of lung cancer, MYC, R, GSPT1, Neoplasm, CDK2, Drug discovery, DSM-IV codes, Autoimmune disease, American College of Rheumatology, Roche, Cancer, Autoimmunity, Finance, Therapy, Patient, ACR, Administration, CIA, VAV1, Pharmaceutical industry, Vaccine, Cryptocurrency

"This has been a pivotal time for Monte Rosa as we announced both our first clinical data and our first major strategic collaboration,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics.

Key Points: 
  • "This has been a pivotal time for Monte Rosa as we announced both our first clinical data and our first major strategic collaboration,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics.
  • Research and Development (R&D) Expenses: R&D expenses for the third quarter of 2023 were $28.3 million, compared to $21.3 million for the third quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the third quarter of 2023 were $8.7 million compared to $7.0 million for the third quarter of 2022.
  • Net Loss: Net loss for the third quarter of 2023 was $34.9 million, compared to $27.3 million for the third quarter of 2022.

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases

Retrieved on: 
Tuesday, November 7, 2023
BCR, Psoriasis, American College, IND, Inflammation, Autoimmunity, Rheumatoid arthritis, HIV disease progression rates, Data, MGD, Poster session, American College of Rheumatology, Multiple sclerosis, Therapy, ACR, Inflammatory bowel disease, CIA, VAV1, Pharmaceutical industry, Vaccine

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data at the American College of Rheumatology (ACR) Convergence Annual Meeting held November 10-15 in San Diego, CA. The data demonstrate that MRT-6160, a novel, highly selective MGD targeting VAV1, attenuated disease progression in a murine collagen-induced arthritis (CIA) model.

Key Points: 
  • The data demonstrate that MRT-6160, a novel, highly selective MGD targeting VAV1, attenuated disease progression in a murine collagen-induced arthritis (CIA) model.
  • In vitro, MRT-6160 induced selective degradation of VAV1, and attenuated TCR- and BCR-mediated activation and function of primary human T- and B-cells.
  • In the CIA model, oral dosing of MRT-6160 elicited rapid VAV1 degradation across multiple tissues in a dose-dependent manner.
  • Over the course of 20 days, MRT-6160 significantly decreased disease progression and endpoint functional scores compared to vehicle and showed a trend towards superior activity compared to an anti-TNF antibody.

Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 10, 2023
Carcinoma, MYC, IPO, AACR, CFA, PD, Pharmacokinetics, Finance, SCLC, VAV1, Research and development, Public expenditure, Patient, Administration, CFO, R, Research, FDA, Therapy, Regulation of tobacco by the U.S. Food and Drug Administration, IND, Food, MGD, Safety, Pharmaceutical industry, G&A

We expect to file an IND application for MRT-6160 in the first half of 2024," said Markus Warmuth, M.D., CEO of Monte Rosa Therapeutics.

Key Points: 
  • We expect to file an IND application for MRT-6160 in the first half of 2024," said Markus Warmuth, M.D., CEO of Monte Rosa Therapeutics.
  • In addition, this morning, Monte Rosa announced the resignation of Ajim Tamboli, CFA, who has served as the Company’s Chief Financial Officer (CFO).
  • General and Administrative (G&A) Expenses: G&A expenses for the second quarter of 2023 were $8.1 million compared to $6.3 million for the second quarter of 2022.
  • Net Loss: Net loss for the second quarter of 2023 was $35.2 million, compared to $26.5 million for the second quarter of 2022.

Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors

Retrieved on: 
Wednesday, July 26, 2023
Therapy, Roche, MGD, Research, Inflammation, VAV1, Patient, Bremelanotide, Drug discovery, Knowledge, Biogen, Manning, Johnson & Johnson, Autoimmunity, Pharmaceutical industry, Momenta

BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors.

Key Points: 
  • BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors.
  • Dr. Manning is a highly accomplished drug discovery leader in the field of autoimmune and inflammatory diseases.
  • Manning brings extensive knowledge and experience in the field of immunology and inflammation to our Board of Directors, and we’re delighted to have him on our team,” said Markus Warmuth, M.D., CEO of Monte Rosa.
  • Dr. Manning has contributed more than 120 scientific publications and patents in the fields of autoimmune diseases, novel therapeutics, and drug discovery.

Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases

Retrieved on: 
Tuesday, May 23, 2023
PK, PD, Autoimmunity, VAV1, Protein, Investigational New Drug, HIV disease progression rates, Patient, Biology, Therapy, IND, GSPT1, MGD, Safety, Disease, Vaccine, Pharmaceutical industry

The Company plans to file an Investigational New Drug (IND) application for MRT-6160 in the first half of 2024 and to develop the molecule as a potential treatment for autoimmune diseases.

Key Points: 
  • The Company plans to file an Investigational New Drug (IND) application for MRT-6160 in the first half of 2024 and to develop the molecule as a potential treatment for autoimmune diseases.
  • “MRT-6160 is a potent, orally bioavailable MGD designed to degrade VAV1, an important protein involved in the signaling pathways of T and B cells.
  • Our in vitro studies have shown that MRT-6160 selectively degrades VAV1 without detectable effects on other proteins.
  • “MRT-6160 is expected to be our second MGD to enter clinical trials, showcasing the continued productivity of our QuEEN™ platform.

Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 11, 2023
Carcinoma, MYC, AACR, PD, American Association for Cancer Research, MBA, Finance, Inflammation, Lung cancer, Oncogene, Monte Rosa, VAV1, Research and development, Public expenditure, Administration, Biology, R, Oncology, Therapy, MGD, Safety, Pharmaceutical industry, G&A

BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the quarter ended March 31, 2023.

Key Points: 
  • BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the quarter ended March 31, 2023.
  • “During the first quarter, we made significant progress with our Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors.
  • General and Administrative (G&A) Expenses: G&A expenses for the first quarter of 2023 were $7.5 million compared to $6.4 million for the first quarter of 2022.
  • Net Loss: Net loss for the first quarter of 2023 was $32 million, compared to $23.9 million for the first quarter of 2022.

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 16, 2023
Lead, Finance, Public expenditure, SCLC, Chemistry, Food and Drug Administration, Horizon, NSCLC, GSPT1, Trial of the century, Lung cancer, PK, Fast Track, MGD, Cytokine, B-cell lymphoma, MTD, American Association for Cancer Research, Index, MYC, Research, AACR, Therapy, PD, Jennifer, Patient, Inflammation, FDA, VAV1, Cancer, Safety, Carcinoma, R, CDK2, Autoimmunity, Drug discovery, DLBCL, Treatment of lung cancer, Drug development, EORTC, Priority review, Process, Administration, Senior, Queen, Accelerated approval (FDA), Food, Research and development, Cryptocurrency, Pharmaceutical industry, G&A, IND

Initiated patient dosing in October of its Phase 1/2 clinical trial evaluating MRT-2359 for the treatment of MYC-driven solid tumors, including lung cancer.

Key Points: 
  • Initiated patient dosing in October of its Phase 1/2 clinical trial evaluating MRT-2359 for the treatment of MYC-driven solid tumors, including lung cancer.
  • When activated, VAV1 relays a signal cascade that results in immune cell activation and the secretion of several pro-inflammatory cytokines.
  • Net Loss: Net loss for the fourth quarter of 2022 was $30.8 million compared to $23.4 million for the fourth quarter of 2021, and $108.5 million for the year ended December 31, 2022, compared to $74.0 million for the year ended December 31, 2021.
  • Cash Position and Financial Guidance: Cash, cash equivalents, restricted cash, and marketable securities as of December 31, 2022, were $268.1 million, compared to $351.4 million as of December 31, 2021.

Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Private Securities Litigation Reform Act, Forward-looking statement, Protein, Finance, Lymphoma, Food, Communication, Research, Lung cancer, VAV1, GSPT1, Proteomics, G&A, COVID-19, MYC, Regulation of tobacco by the U.S. Food and Drug Administration, Therapy, R, Exercise, Annual report, NASDAQ, Harrison Avenue, Achievement, U.S. Securities and Exchange Commission, Public expenditure, MGD, Publication, Program, Research and development, Clinical trial, Monte Rosa, Terminology, Conference, Patient, Treatment, Growth, Neoplasm, CEO, Administration, ETH, FDA, Pharmaceutical industry, Fine chemical

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the third quarter, ended September 30, 2022.

Key Points: 
  • General and Administrative (G&A) Expenses: G&A expenses for the third quarter of 2022 were $7.0 million, compared to $4.8 million for the third quarter of 2021.
  • G&A expenses included non-cash stock-based compensation of $1.5 million for the third quarter of 2022, compared to $1.0 million for the same period in 2021.
  • Net Loss: Net loss for the third quarter of 2022 was $27.3 million, compared to $19.8 million for the third quarter of 2021.
  • Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel molecular glue degrader (MGD) medicines.

Monte Rosa Therapeutics Announces First Development Candidate and Reports Third Quarter 2021 Financial Results and Business Updates

Retrieved on: 
Wednesday, November 10, 2021
Lymphatic system, VAV1, Biodata, Private Securities Litigation Reform Act, Therapy, R, NASDAQ, CEO, Oncogene, Food, N-Myc, Rational design, BCL11A, Cell death, Russell, COVID-19, Administration, Research, Regulation of tobacco by the U.S. Food and Drug Administration, Squamous cell carcinoma, Program, Finance, Proteomics, Cancer, AACR, Public expenditure, File, Multiple myeloma, Protein, MGD, Research and development, Company, GLOBE, Conference, CDK2, Large-cell lung carcinoma, Myc, U.S. Securities and Exchange Commission, GSPT1, Precision medicine, Apoptosis, Cell, FDA, IND, Fine chemical, Pharmaceutical industry, Video game

BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue-based precision medicines, today reported business highlights and financial results for the third quarter, ended Sept. 30, 2021.

Key Points: 
  • Owen Wallace, Ph.D., Chief Scientific Officer of Monte Rosa, added, Advancing our first development candidate into IND-enabling activities is one of the most important milestones for our company to date.
  • Selected first development candidate, MRT-2359, targeting GSPT1 and initiated IND-enabling activities.
  • Net Loss: Net loss for the third quarter of 2021 was $19.8 million, compared to $6.6 million for the third quarter of 2020.
  • Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel molecular glue degrader precision medicines.